These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 21224028)

  • 21. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
    Kalantarinia K; Okusa MD
    Curr Diab Rep; 2006 Feb; 6(1):8-16. PubMed ID: 16522275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome studies in diabetic nephropathy.
    Mohanram A; Toto RD
    Semin Nephrol; 2003 May; 23(3):255-71. PubMed ID: 12838494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
    Yamout H; Lazich I; Bakris GL
    Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compelling drug indications in diabetic and nondiabetic nephropathy.
    Ritz E; Dikow R; Zeier M
    Curr Hypertens Rep; 2004 Aug; 6(4):293-9. PubMed ID: 15257864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients.
    Isaacs AN; Vincent A
    J Clin Pharm Ther; 2016 Apr; 41(2):111-5. PubMed ID: 26850093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
    Hommel E
    J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity.
    Baba T; Ishizaki T
    Drugs; 1992 Apr; 43(4):464-89. PubMed ID: 1377114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
    Mansur SJ; Hage FG; Oparil S
    Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pathogenesis and management of hypertension in diabetic kidney disease.
    Van Buren PN; Toto RD
    Med Clin North Am; 2013 Jan; 97(1):31-51. PubMed ID: 23290728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure, diabetes and diabetic nephropathy.
    Chantrel F; Moulin B; Hannedouche T
    Diabetes Metab; 2000 Jul; 26 Suppl 4():37-44. PubMed ID: 10922972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
    Bakris GL
    Postgrad Med; 2003 May; 113(5):35-40, 43-4, 50. PubMed ID: 12764895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic Issues in treating hypertension in CKD.
    Sica DA
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):42-7. PubMed ID: 21224029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigational drugs for diabetic nephropathy.
    Cortinovis M; Cattaneo D; Perico N; Remuzzi G
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1487-500. PubMed ID: 18808309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.